THERAPY DOSSIER · th-f5dc4179ab70

Prospero homeobox 1 (Prox1) small interfering RNA

Other · No ChEMBL entity exists for a gene-specific siRNA reagent, so ChEMBL was not queried. ClinicalTrials.gov searched for 'Prox1 siRNA OR prospero homeobox': 0 hits. No human trial targets PROX1 with siRNA.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL entity exists for a gene-specific siRNA reagent, so ChEMBL was not queried. ClinicalTrials.gov searched for 'Prox1 siRNA OR prospero homeobox': 0 hits. No human trial targets PROX1 with siRNA.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26348636 ↗2015Reported benefit

Inhibition of Lymphangiogenesis and Hemangiogenesis in Corneal Inflammation by Subconjunctival Prox1 siRNA Injection in Rats.

RatChemical/toxinmaleSubconjunctival injection

Model: Alkali burn-induced inflammatory corneal neovascularisation

Subconjunctival Prox1 siRNA significantly inhibited alkali burn-induced corneal lymphangiogenesis and haemangiogenesis compared with scrambled siRNA, to an extent comparable with bevacizumab, and also reduced macrophage and leukocyte infiltration and downregulated LYVE-1, podoplanin, VEGFR2 and VEG…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…